In addition, a high expression of the transporter was detected in non-small cell lung carcinoma and squamous cell carcinoma (on the protein level), as well as in MYCN-amplified neuroblastoma, colorectal carcinoma and urothelial bladder carcinomas (on the mRNA level) [50,51,52]. Here, MYCN is linked to bladder transitional cell carcinoma.